# Evaluate the Safety and Efficacy of CLL1 CAR-T in Patients With R/R AML

> **NCT05467202** · PHASE1 · UNKNOWN · sponsor: **Zhejiang University** · enrollment: 20 (estimated)

## Conditions studied

- AML

## Interventions

- **DRUG:** CLL1 CAR-T

## Key facts

- **NCT ID:** NCT05467202
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-01
- **Primary completion:** 2024-08-02
- **Final completion:** 2025-08-02
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05467202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05467202, "Evaluate the Safety and Efficacy of CLL1 CAR-T in Patients With R/R AML". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05467202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*